Total trials
523
Active
5
Phase 3
146
Total enrollment
182,029
Pipeline matrix
Showing 24 of 24 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| avacincaptad pegol | — | — | — | — | — | 1 | |
| Gilteritinib | — | — | — | 3 | |||
| Cytarabine | — | — | — | — | 2 | ||
| Mitoxantrone | — | — | — | — | — | 1 | |
| Etoposide | — | — | — | — | — | 1 | |
| G-CSF | — | — | — | — | — | 1 | |
| Fludarabine | — | — | — | — | — | 1 | |
| ASP2246 | — | — | — | — | — | 1 | |
| Docetaxel | — | — | — | — | 4 | ||
| Gemcitabine | — | — | — | — | 3 | ||
| Carboplatin | — | — | — | — | — | 2 | |
| Setidegrasib | — | — | — | — | — | 1 | |
| Cetuximab | — | — | — | — | — | 1 | |
| Leucovorin | — | — | — | — | — | 1 | |
| Oxaliplatin | — | — | — | — | — | 1 | |
| Fluorouracil | — | — | — | — | — | 1 | |
| Irinotecan | — | — | — | — | — | 1 | |
| Nanoparticle albumin-bound-paclitaxel | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | — | 1 | |
| Pemetrexed | — | — | — | — | — | 1 | |
| Liposomal Irinotecan | — | — | — | — | — | 1 | |
| ASP5834 | — | — | — | — | — | 1 | |
| panitumumab | — | — | — | — | — | 1 |
Next readouts
- 2023-12-25
- 2027-06-30
- 2028-11-30
- 2028-12-31
- 2030-02-28
Top conditions
- Healthy34
- Healthy Subjects29
- Kidney Transplantation28
- Overactive Bladder21
- Type 2 Diabetes Mellitus20
- Urinary Bladder, Overactive17
- Liver Transplantation17
- Healthy Volunteers17
Frequently asked questions about Astellas Pharma Inc
- How many clinical trials does Astellas Pharma Inc have on ClinicalTrials.gov?
- Astellas Pharma Inc is listed as the lead sponsor on 523 clinical trials in ClinicalTrials.gov, 5 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Astellas Pharma Inc's trials are in Phase 3?
- 146 of Astellas Pharma Inc's trials are in Phase 3, spread across 24 active drug programs.
- What therapeutic areas does Astellas Pharma Inc focus on?
- Astellas Pharma Inc's most-studied conditions on ClinicalTrials.gov are Healthy, Healthy Subjects, Kidney Transplantation, Overactive Bladder, Type 2 Diabetes Mellitus.
- When are Astellas Pharma Inc's next clinical trial readouts?
- Astellas Pharma Inc has 5 upcoming primary-completion readouts tracked here; the soonest is “A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation”, expected around 2023-12-25.